Poseida Therapeutics, Inc.

Translating best-in-class gene engineering technologies into lifesaving cell therapies.

The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida’s lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac™ DNA Modification System, TAL-CLOVER™ and Cas-CLOVER™ site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE).

Poseida Therapeutics Logo

Visit Website

October 10, 2019 in Portfolio, Poseida Therapeutics, Inc.

Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer

SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced Kerry Ingalls has joined the company as Chief…
Read More
May 13, 2019 in Portfolio, Poseida Therapeutics, Inc.

Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma

SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced the United States…
Read More
April 22, 2019 in Portfolio, Poseida Therapeutics, Inc., Rapha Capital Management

Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals

MIAMI, April 22, 2019 /PRNewswire/ -- Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, and their associated entities announced today their participation in a Series C financing for…
Read More
April 22, 2019 in Portfolio, Poseida Therapeutics, Inc.

Poseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round

The race to bring CAR-T cell therapy to multiple myeloma, a persistent and deadly cancer of the bone marrow, continued on Monday with a fresh round of funding for Poseida Therapeutics. Swiss…
Read More
February 21, 2019 in Portfolio, Poseida Therapeutics, Inc.

Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks

Poseida Therapeutics, Inc. Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks Key Patent Covers Manufacture of Therapeutic Products Containing a High Percentage of T…
Read More
January 6, 2019 in Portfolio, Poseida Therapeutics, Inc.

Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T

Is there enough enthusiasm among biotech investors to push through a $115 million-plus IPO on the latest biotech staking out their claim with a new-and-improved BCMA CAR-T therapy? Poseida Therapeutics…
Read More
December 3, 2018 in Portfolio, Poseida Therapeutics, Inc.

Poseida Therapeutics: Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today provided an update on…
Read More
November 19, 2018 in Portfolio, Poseida Therapeutics, Inc.

Poseida Therapeutics: FDA Grants Poseida’s P-BCMA-101 Regenerative Medicine Advanced Therapy (RMAT) Status for Treatment of Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed or refractory multiple myeloma. Preliminary…
Read More
November 2, 2018 in Portfolio, Poseida Therapeutics, Inc.

Poseida Therapeutics: BCMA in the spotlight as ASH abstracts drop

Drugs which target the BCMA receptor look set to feature prominently at this year’s American Society of Haematology (ASH) meeting, with new trial results expected for several of the leading…
Read More
September 5, 2018 in Portfolio, Poseida Therapeutics, Inc.

Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma

Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and only a single incidence of suspected cytokine release syndrome P-BCMA-101…
Read More
July 20, 2018 in Portfolio, Poseida Therapeutics, Inc.

Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer

SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that the…
Read More
April 4, 2018 in Portfolio, Poseida Therapeutics, Inc.

Poseida raises $30.5 million for cancer cell therapy

San Diego’s Poseida Therapeutics has raised $30.5 million in venture capital funding, the cancer therapy developer said Tuesday. The Series B financing round was led by new investor Longitude Capital, along…
Read More